Loading...
*  Proto-oncogene proteins C-bcl-2 | definition of Proto-oncogene proteins C-bcl-2 by Medical dictionary
Looking for online definition of Proto-oncogene proteins C-bcl-2 in the Medical Dictionary? Proto-oncogene proteins C-bcl-2 explanation free. What is Proto-oncogene proteins C-bcl-2? Meaning of Proto-oncogene proteins C-bcl-2 medical term. What does Proto-oncogene proteins C-bcl-2 mean?
  http://medical-dictionary.thefreedictionary.com/Proto-oncogene+proteins+C-bcl-2
*  Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant - Zurich Open...
TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents ...
  http://www.zora.uzh.ch/id/eprint/99609/
*  2017/18 ICD-10-CM Diagnosis Code C82.50: Diffuse follicle center lymphoma, unspecified site
Free, official coding info for 2018 ICD-10-CM C82.50 - includes detailed coding rules & notes, synonyms, ICD-9-CM conversion, index & annotation crosswalks, DRG grouping and more.
  http://www.icd10data.com/ICD10CM/Codes/C00-D49/C81-C96/C82-/C82.50
*  Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of adult NHL cases. (See.)The molecular pathogenesis of DLBCL is a complex, multistep process that ulti
  https://www.uptodate.com/contents/pathobiology-of-diffuse-large-b-cell-lymphoma-and-primary-mediastinal-large-b-cell-lymphoma
*  Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B‑cell lymphoma
Lysosomal protein transmembrane 4β (LAPTM4B) is an oncogene that is overexpressed in a number of various types of human cancer. There are two known alleles of LAPTM4B: LAPTM4B*1 and LAPTM4B*2. The present study assessed the association between LAPTM4B polymorphisms and the susceptibility to diffuse large B‑cell lymphoma (DLBCL) and its prognosis. LAPTM4B genotypes were determined using polymerase chain reaction analysis in 164 DLBCL and 350 healthy control cases. The association between LAPTM4B polymorphisms and the risk of DLBCL was analyzed using unconditional logistic regression. Differences in patient survival were calculated using Kaplan‑Meier analysis. The present study indicated no significant differences (P>0.05) in the frequency of LAPTM4B*2 alleles between DLBCL cases (26.5%) and controls (24.1%). The risk of DLBCL was slightly increased in cases with the LAPTM4B*1/2 genotype [odds ratio ...
  https://www.spandidos-publications.com/ol/15/1/264/abstract
*  A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B cell...
Central nervous system dissemination is a relatively uncommon but almost always fatal complication in diffuse large B cell lymphoma patients. Optimal therapy for central nervous involvement in this malignancy has not been established. In this paper, we aimed to evaluate the therapeutic effect of E7123, a celecoxib derivative that inhibits focal adhesion signaling, in a novel xenograft model of diffuse large B cell lymphoma with central nervous system involvement. Cells obtained after disaggregation of HT subcutaneous tumors (HT-SC cells) were intravenously injected in NOD/SCID mice. These mice received oral vehicle or 75 mg/kg of E7123 daily until they were euthanized for weight loss or signs of sickness. The antitumor effect of E7123 was validated in an independent experiment using a bioluminescent mouse model. Intravenously injected HT-SC cells showed higher take rate and higher central nervous system tropism (associated with increased expression of β1-integrin and p130Cas ...
  http://www.haematologica.org/content/early/2013/05/03/haematol.2012.071811
*  Diffuse large B cell lymphoma - wikidoc
For patient information click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Synonyms and Keywords: DLBCL; Diffuse large B-cell lymphoma; Large B cell lymphoma; Diffuse lymphoma ...
  http://es.wikidoc.org/index.php/Diffuse_large_B_cell_lymphoma
*  Initial treatment of limited stage (I/II) follicular lymphoma
Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is mea
  https://www.uptodate.com/contents/initial-treatment-of-limited-stage-i-ii-follicular-lymphoma
*  Diffuse large cell lymphoma definition | Drugs.com
Definition of diffuse large cell lymphoma. Provided by Stedman's medical dictionary and Drugs.com. Includes medical terms and definitions.
  https://www.drugs.com/dict/diffuse-large-cell-lymphoma.html
*  Mediastinal diffuse large B cell lymphoma | Radiology Case | Radiopaedia.org
US-guided biopsy was subsequently performed on the superior mediastinal mass. Histopathology: DIAGNOSIS: Mediastinal mass biopsy: Non-Hodgkins B-cell lymphoma, morphologically consistent with diffuse large B-cell lymphoma.
  https://radiopaedia.org/cases/mediastinal-diffuse-large-b-cell-lymphoma
*  C-bcl-2 | definition of C-bcl-2 by Medical dictionary
Looking for online definition of C-bcl-2 in the Medical Dictionary? C-bcl-2 explanation free. What is C-bcl-2? Meaning of C-bcl-2 medical term. What does C-bcl-2 mean?
  https://medical-dictionary.thefreedictionary.com/C-bcl-2
*  A systems view of Drosophila segmentation | Genome Biology | Full Text
One of the most intensively studied processes in animal development is the division of the embryonic Drosophila epidermis (ectoderm) into visible segments, a process that lays the foundations for the segmented structure of the adult insect. Segmentation is governed by a program of sequential gene expression that is one of the best-defined genetic cascades in animal development [1]. It is put into motion by three maternal gene regulatory proteins - Bicoid, Hunchback and Caudal - which specify an initial 'pre-segmentation' pattern along the anterior-posterior axis, while the anterior and posterior ends of the body are specified independently by the localized activation of the maternal receptor tyrosine kinase Torso. The principal target genes of these maternal factors in the embryo's genome are known as gap genes, as their lack leads to gaps in the body pattern. The gap genes, ...
  https://genomebiology.biomedcentral.com/articles/10.1186/gb-2008-9-2-207
*  A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) - No Study Results...
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... ...
  https://clinicaltrials.gov/ct2/show/results/NCT01238692
*  Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy - Full Text View -...
Phase I:. Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3 patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day, starting on day 2 of cycle 1.. 4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID) (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort -1), depending on the observed toxicities.. Phase II:. Up to 115 patients will be recruited and treated with tazemetostat at the MTD and RCHOP. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat at the MTD every day, starting on day 2 of cyle 1. ...
  https://clinicaltrials.gov/ct2/show/NCT02889523?term=tazemetostat&rank=10
*  Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects a
  http://www.knowcancer.com/cancer-trials/NCT01282476/
*  Mediastinum - Diffuse large B cell lymphoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
  http://pathologyoutlines.com/topic/mediastinumdiffuselargeB.html
*  R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug, bevacizumab and whether this treatment is feasible in patients wi
  http://www.knowcancer.com/cancer-trials/NCT00788606/
*  Exbio antibodies - Mouse Monoclonal to CD273 / PD-L2 24F.10C12 (IgG2a)
CD273 / PD-L2 (programmed death ligand-1), also known as B7-DC, is a member of the B7 family of regulatory proteins. It costimulates the proliferation of T cells, and mediates IFN gamma production. Ligation of CD273 on dendritic cells enhances dendritic cell activation and T cell responses. When interacting with CD279, it can act as a coinhibitor of the T cell function. CD273 expression is a useful marker to distinguish primary mediastinal B cell lymphoma from other diffuse large B cell lymphomas ...
  http://www.exbio.cz/products/clone.py?idclone=CLO000000000000671
*  TORCH - University of Birmingham
TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).
  https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/trials/haematology/torch/index.aspx
*  TMD8: post #1
TMD8 - posted in Tissue and Cell Culture: I recently tried to culture TMD8 cells (a diffuse large B cell lymphoma cell line) in the lab. I used standard culture condition: RPMI + 10% FCS (or IMDM + 10% human serum) + P/S + 50uM beta-ME. The cells were got from another lab in medium. They grew for a short period of time and then began to die quickly. I tried many ways to rescue the cells. I recovered live cells from the mass of dead cells by spin down extremely slow (~200 to 300 rpm) and...
  http://www.protocol-online.org/forums/topic/18658-tmd8/
*  Mathematics Faculty: Publications since January 2016
Reddy, A; Zhang, J; Davis, NS; Moffitt, AB; Love, CL; Waldrop, A; Leppa, S; Pasanen, A; Meriranta, L; Karjalainen-Lindsberg, M-L; Nørgaard, P; Pedersen, M; Gang, AO; Høgdall, E; Heavican, TB; Lone, W; Iqbal, J; Qin, Q; Li, G; Kim, SY; Healy, J; Richards, KL; Fedoriw, Y; Bernal-Mizrachi, L; Koff, JL; Staton, AD; Flowers, CR; Paltiel, O; Goldschmidt, N; Calaminici, M; Clear, A; Gribben, J; Nguyen, E; Czader, MB; Ondrejka, SL; Collie, A; Hsi, ED; Tse, E; Au-Yeung, RKH; Kwong, Y-L; Srivastava, G et al., Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma., Cell, vol. 171 no. 2 (October, 2017), pp. 481-494.e15 [doi] [abs] ...
  https://fds.duke.edu/db?pubs-39-122-0-0-1-16-0
*  Bcor - Drugs.com
Bcor is a medicine available in a number of countries worldwide. A list of US medications equivalent to Bcor is available on the Drugs.com website.
  https://www.drugs.com/international/bcor.html
*  Neuro Laz - Drugs.com
Neuro Laz is a medicine available in a number of countries worldwide. A list of US medications equivalent to Neuro Laz is available on the Drugs.com website.
  https://www.drugs.com/international/neuro-laz.html
*  Pullex Silverwood - Ochrana dreva - lazúrovacia - Ochrana dreva v exteriéri - Produkty & riešenia - ADLER Lacke
Použité účinné látky poskytujú podľa platnej rakúskej normy ÖNORM B3802-2 resp. DIN 68800-3 požadovanú ochranu pred zamodraním (skúška podľa EN 152-1), drevokazným hubám (skúška podľa EN 113) a preventívne voči napadnutiu hmyzom(skúška podľa EN 46). Množstvo nánosu pri normových skúškach cca 200 g/m2 (uznávací certifikát č. 6/93 ...
  http://www.adler.sk/sk/produkty-riesenia/srodki-ochrony-drewna-na-zewn-549/srodki-ochrony-drewna-lazur-548/pullex-silverwood-10097/